TABLE 2.

The application of oncolytic virus for cancer treatment.

	Time to market	Virus type	Range of application	Efficacy	Side effects
RIGVIR	2004	Human intestinal cytopathic orphan virus	Melanoma	Among melanoma patients, the overall rate (3-year and 5-year) of rigvir patients and control were 78–84%, 66–81% and 54–57%, 42–56%	Fatigue, sleepiness, and dyspepsia (reversible, lasted for a couple of days and did not require treatment)
Oncorine	2005	Adenovirus	Head and neck cancer	Oncorine plus chemotherapy-treated head and neck cancer patients (78.8%) have a significantly higher response rate compared with the chemotherapy-treated head and neck cancer patients (39.6%)	Fever (45.7%), local site pain (28.3%), flu-like symptoms (9.8%), leukopenia, decreasing platelets, liver malfunctions, alopecia and nausea (all of which were tolerated well)
0.T-vec	2015	Herpes simplex virus	Local treatment of unresectable lesions of recurrent melanoma after surgical excision	Treat advanced melanoma. The overall response rate was 26%. The combined use of T-vec and PD-1 showed a tumor remission rate as high as 62%, of which 33% was complete remission. The remission rate of T-vec alone is 30% to 40%	Chills, fever, injection point pain, nausea, flu-like symptoms, and fatigue. And the most common serious side effects were disease progression, cellulitis, and fever, none of which occurred in more than 2% of cases